Linked Life Data

12192266

Source:http://linkedlifedata.com/resource/pubmed/id/12192266

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-8-22
pubmed:abstractText
Targeted therapy using monoclonal antibodies against a tumor-specific antigen is now an established mode of therapy in the management of malignant lymphomas. Radioimmunotherapy, a novel way of delivering systemic radiotherapy concurrently with immunotherapy, has finally appeared on the horizon, with promising results. Recent clinical trials have demonstrated the safety and efficacy of radioimmunoconjugates. Durable antitumor responses have been achieved, even in heavily pretreated patients. The optimal position that these novel agents should take in the algorithm of lymphoma therapy remains to be defined.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1040-8746
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
484-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Radioimmunotherapy in non-Hodgkin lymphoma.
pubmed:affiliation
Roswell Park Cancer Institute, Buffalo, New York 14263, USA. asher.chanan-khan@roswellpark.org
pubmed:publicationType
Journal Article, Review